What Is BIA-ALCL? A Plain-English Guide for Implant Patients
Breast implant-associated anaplastic large cell lymphoma — BIA-ALCL — is a rare cancer of the immune system, not a breast cancer. It develops when T-lymphocytes (white blood cells) in the fluid or fibrous capsule surrounding a breast implant undergo malignant transformation. The disease was first identified in the 1990s but not formally recognized as a distinct entity until the World Health Organization classified it in 2016. The FDA established a definitive causal link between BIA-ALCL and textured breast implants in 2019, and the evidence overwhelmingly implicates Allergan's BIOCELL macro-textured surface: as of June 2023, 1,079 of 1,264 reported BIA-ALCL cases worldwide (85%) involved Allergan products. The FDA estimated that Allergan BIOCELL recipients face approximately a 6x higher risk than patients with other manufacturers' implants.
BIA-ALCL Symptoms — What to Watch For
The hallmark symptom of BIA-ALCL is late-onset seroma — a sudden, persistent accumulation of fluid around the breast implant — that appears an average of 8 to 10 years after implant placement. This is different from the normal post-surgical fluid that resolves within weeks of the original surgery. Additional symptoms include: sudden breast swelling or asymmetry; a palpable lump in the breast or axilla (armpit); breast pain or tenderness without infection; skin redness or rash over the implant; and enlarged lymph nodes in the armpit. Any Allergan BIOCELL implant patient who experiences late-onset breast changes should request an ultrasound-guided aspiration — the fluid is tested for malignant lymphoma cells. Early detection of BIA-ALCL dramatically improves both outcomes and legal compensation.
BIA-ALCL Staging (IA Through IV) and What Each Stage Means for Your Case
BIA-ALCL is staged using the MD Anderson Cancer Center Solid Tumor Staging System. Stage IA: lymphoma cells are found only in the seroma fluid or on the inner surface of the capsule — the most favorable stage, typically curable with en bloc surgical removal alone. Stage IB: lymphoma has penetrated the outer surface of the capsule. Stage IIA: single regional lymph node is involved. Stage IIB: multiple lymph nodes involved. Stage III: disease has spread to adjacent structures (chest wall, skin, or breast tissue). Stage IV: distant metastases to organs such as the liver, lungs, or bone — the most advanced and serious stage. For legal purposes, stage at diagnosis is the single most important factor in determining compensation. Stage IA cases are estimated to settle in the $50,000–$300,000 range; Stage IV cases may command $1,000,000–$3,000,000 or more based on comparable medical device MDL outcomes. The 8 to 10 year latency between implant placement and BIA-ALCL diagnosis means many women were implanted in the 2000s and 2010s and are entering peak diagnosis risk now.
BIA-ALCL Treatment by Stage
Stage IA treatment: complete en bloc capsulectomy (implant plus entire capsule removed as one specimen). This is curative in most Stage IA cases without chemotherapy. Stage IB–III treatment: surgery followed by systemic chemotherapy — most commonly CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or CHOP with brentuximab vedotin (an anti-CD30 antibody-drug conjugate with strong efficacy in BIA-ALCL). Radiation may be added for localized lymph node involvement. Stage IV treatment: intensive multi-agent chemotherapy, potentially including autologous stem cell transplant for eligible patients. All stages require post-treatment surveillance with PET-CT imaging. The NCCN recommends referral to a lymphoma specialist with BIA-ALCL experience, as most oncologists have limited direct experience with this specific entity.
Frequently Asked Questions
Related Pages
BIA-ALCL staging — from Stage IA (confined to seroma fluid) through Stage IV (distant metastases) — is the single most important factor in determining the value of an Allergan breast implant lawsuit. Early-stage cases are curable; advanced stages require chemotherapy and carry worse prognosis and significantly higher compensation.
Learn moreThe July 24, 2019 Allergan BIOCELL recall was the largest breast implant recall in FDA history. It covered 33+ product lines after the FDA determined BIOCELL recipients faced a 6x elevated risk of BIA-ALCL lymphoma. French regulators had recalled the same product a year earlier in 2018.
Learn moreBreast implant illness (BII) is a constellation of systemic symptoms — fatigue, brain fog, joint pain, hair loss — reported by implant patients. Unlike BIA-ALCL, BII is not yet a formally recognized diagnosis, but BII plaintiffs with Allergan BIOCELL implants are included in MDL 2921 litigation.
Learn moreThe Allergan Natrelle 410 Highly Cohesive Anatomically Shaped implant was the most widely used recalled product and is at the center of MDL 2921. McGhan textured implants — an earlier Allergan brand — are also covered by the July 2019 recall. If you received either product, you may have a claim.
Learn moreWomen who received Allergan BIOCELL textured implants or tissue expanders as part of post-mastectomy breast reconstruction after breast cancer are a distinct and especially sympathetic plaintiff class in MDL 2921. They fought breast cancer once — and Allergan's recalled product put them at risk of a second cancer.
Learn moreThe FDA does not recommend prophylactic removal of Allergan BIOCELL implants for asymptomatic patients. However, women who chose explantation after the recall may have legal claims for surgery costs. Women with BIA-ALCL symptoms require immediate medical evaluation — not observation.
Learn moreNo global Allergan BIOCELL settlement has been announced as of February 2026. The October 2026 bellwether trial will drive settlement negotiations. Based on comparable medical device MDLs, BIA-ALCL Stage IA cases may settle in the $50,000–$300,000 range; Stage IV cases may command $1,000,000–$3,000,000 or more.
Learn moreThe statute of limitations for Allergan BIOCELL claims is typically 2 to 3 years from discovery — meaning from BIA-ALCL diagnosis, not from implant placement or recall date. Discovery rule protections apply in most states. Consult an attorney immediately — deadlines are strict and MDL tolling is not automatic.
Learn moreYou may qualify if you received Allergan BIOCELL textured implants (for augmentation or reconstruction), were diagnosed with BIA-ALCL, or had your implants removed due to the recall. You do not need a cancer diagnosis to file. Implants already removed do not disqualify you.
Learn moreAllergan Breast Implant Lawsuit Lawsuit
Allergan (now owned by AbbVie) manufactured BIOCELL textured breast implants — including the widely used Natrelle 410 — that were found to cause breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare but serious T-cell lymphoma of the immune system. The FDA determined that women with Allergan BIOCELL implants were approximately six times more likely to develop BIA-ALCL than women with implants from other manufacturers. On July 24, 2019, Allergan initiated a worldwide recall of all BIOCELL textured breast implants and tissue expanders. As of June 2023, the FDA had received 1,264 BIA-ALCL reports globally, with 1,079 — representing 85% of all cases — involving Allergan implants. Sixty-three deaths have been reported, with 37 linked to Allergan products. MDL 2921, In re Allergan BIOCELL Textured Breast Implant Products Liability Litigation, is pending before Judge Michael Martinotti in the District of New Jersey with approximately 1,400 cases. The first bellwether trial is scheduled for October 2026. Women who received Allergan BIOCELL textured implants, were diagnosed with BIA-ALCL, or underwent implant removal due to the recall may have viable legal claims.
View full case overview